ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,863,613 | -51.9% | 350,963 | -13.7% | 0.00% | – |
| Q2 2023 | $3,874,469 | -78.3% | 406,555 | -74.9% | 0.00% | -100.0% |
| Q1 2023 | $17,839,514 | +404.3% | 1,621,774 | +578.5% | 0.00% | – |
| Q4 2022 | $3,537,761 | +22.4% | 239,038 | +58.0% | 0.00% | – |
| Q3 2022 | $2,891,000 | +254.3% | 151,257 | +295.0% | 0.00% | – |
| Q2 2022 | $816,000 | +322.8% | 38,295 | +283.0% | 0.00% | – |
| Q1 2022 | $193,000 | -23.1% | 10,000 | -17.4% | 0.00% | – |
| Q4 2021 | $251,000 | +60.9% | 12,110 | +86.0% | 0.00% | – |
| Q3 2021 | $156,000 | -12.4% | 6,510 | -0.4% | 0.00% | – |
| Q2 2021 | $178,000 | -85.5% | 6,533 | -84.6% | 0.00% | – |
| Q1 2021 | $1,225,000 | +768.8% | 42,361 | +746.4% | 0.00% | – |
| Q4 2020 | $141,000 | +6.8% | 5,005 | +10.8% | 0.00% | – |
| Q3 2020 | $132,000 | +15.8% | 4,519 | +19.7% | 0.00% | – |
| Q2 2020 | $114,000 | -18.0% | 3,776 | -19.2% | 0.00% | – |
| Q1 2020 | $139,000 | – | 4,672 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |